Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21 Leukemia 9 Gastrointestinal Stromal Tumors 4 Philadelphia Chromosome 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, Myeloid 3 Bone Marrow Diseases 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Myeloproliferative Disorders 2 Hematologic Neoplasms 2 Bronchiolitis Obliterans Syndrome 2 Sarcoma 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Hematologic Diseases 1

Interventions

Leucovorin 22 Fluorouracil 22 Gemcitabine 21 Capecitabine 21 Paclitaxel 20 Docetaxel 20 Irinotecan 15 Carboplatin 15 Radiosurgery 14 Oxaliplatin 13 Cisplatin 13 Bevacizumab 13 Zoledronic Acid 12 pembrolizumab 11 Radiotherapy 11 Fulvestrant 11 palbociclib 9 Pemetrexed 9 Drug Therapy 9 130-nm albumin-bound paclitaxel 9 Surgical Procedures, Operative 7 Letrozole 7 Ibandronic Acid 7 abemaciclib 6 Trastuzumab 6 Prednisone 6 Vinorelbine 5 Folfox protocol 5 Floxuridine 5 Doxorubicin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasm Metastasis × nilotinib × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡